Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Gilead Sciences in a report ...

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Biogen in a research note ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday and set a price ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...

U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...

Upstart investment bank SVB Leerink is no longer keeping mum on its ambitions to push into the red hot technology, media, and telecommunications market. The dealmaking unit of SVB Financial Group ...

Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...

Fintel reports that on February 6, 2025, Leerink Partners downgraded their outlook for Hologic (WBAG:HOLX) from Outperform to Market Perform. There are 1,442 funds or institutions reporting ...

Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform to Outperform. As of January 29, 2025, the average one-year price ...